Home Financing Tags

View the Latest: Financing

Filter

List Grid

41 - 50 of 546 Results

  • The Facts About Medicare Spending

    Interactive

    This interactive provides the facts on Medicare spending. Medicare, which serves 65 million people and accounts for 12 percent of the federal budget and 20 percent of national health spending, is at the heart of discussions about health expenditures and affordability. Explore data on enrollment growth, Medicare spending trends overall and per person, growth in Medicare spending relative to private insurance, spending on benefits and Medicare Advantage, Part A trust fund solvency challenges, and growth in out-of-pocket spending.

  • FAQs on Medicare Financing and Trust Fund Solvency

    Issue Brief

    In discussions of Medicare’s financial condition, attention frequently centers on one specific measure—the solvency of the Medicare Hospital Insurance (HI) trust fund, out of which Medicare Part A benefits are paid. Based on current projections from the Medicare Board of Trustees, the HI trust fund is projected to be depleted in 2036, 12 years from now. These FAQs answer key questions about Medicare financing and trust fund solvency.

  • Medicare 101

    Feature

    This Health Policy 101 chapter explores Medicare, a federal health insurance program covering more than 66 million people, established in 1965 for people age 65 or older and later expanded to cover people under age 65 with long-term disabilities. In addition to detailing Medicare eligibility, coverage, and spending, the chapter examines the increased role of private plans in providing benefits and the financing challenges posed by increasing health care costs and an aging population.

  • Medicaid 101

    Feature

    This Health Policy 101 chapter explores Medicaid, the primary U.S. program providing comprehensive coverage of health care and long-term services and supports to nearly 90 million low-income people. Originating in 1965 and expanding with the Affordable Care Act, the chapter reviews Medicaid's evolution and its joint federal and state financing and administration. It discusses how state-level flexibility in managing Medicaid leads to variation in coverage, spending, health care delivery, and access across different states.

  • International Comparison of Health Systems

    Feature

    This Health Policy 101 chapter explores the performance of the U.S. health system on a number of cost, outcomes, and quality measures by comparing it with those in similarly large and wealthy OECD nations. It highlights that despite significant spending, Americans have shorter life expectancies and encounter more barriers to health care, influenced by both the health system's structure and broader socioeconomic factors.

  • Donor Government Funding for Family Planning in 2022

    Report

    This report provides an analysis of donor government funding to address family planning in low- and middle-income countries in 2022, which totaled US$1.35 billion and was a decline of 9% (US$129 million) compared to the 2021 amount (US$1.48 billion). While the decline was due to decreases in funding by most donor governments, a significant share can be attributed to exchange rate fluctuations resulting from the rise in value of the U.S. dollar against most currencies during 2022.

  • Global Health Funding in the FY 2024 Final Appropriations Bill

    Fact Sheet

    Updated: March 25, 2024 On March 23, 2024, the President signed the second package of final FY 2024 appropriations bills, otherwise known as the “Further Consolidated Appropriations Act, 2024,” which was released by the House and Senate Appropriations Committees on March 20, 2024, passed by the House on March 22, 2024 and passed by the…

  • Gross Medicare Spending on Ozempic and Other GLP-1s Is Already Skyrocketing – Even Though Medicare Cannot Cover The Drugs for Weight Loss

    News Release

    A KFF analysis shows that gross total Medicare spending on Ozempic and other similar drugs has increased dramatically in recent years – even though Medicare is explicitly prohibited by law from covering the drugs for obesity. That’s because Medicare now covers the drugs, known as GLP-1s, for other medically accepted indications, including to treat diabetes.